I get it. I just believe that the bad is priced in. This is well off its high of $3 for Q3 earnings. The earnings were actually good so Jason is probably scratching his head when sitting on the pot at night. LOL Another point is that I was bashing this stock like crazy with the quotes from the filings during the run over .03 in February when the OTC traders lost their minds, so I wouldn't credit my posts as having a lot of influence.
I went back over my valuation scenarios again. What I did was took the total current liabilities for Q3 2020 of $9,656,268 then subtracted the gross profit $591,912 and got $9,064,356. Take this number and divide by the number of outstanding shares 303,539 (post split) and arrive at -$29.86 a share, negative value of course. Mid November 2020 the stock was trading at $12 to $14 a share post split valuation.
Now take the 2021 numbers total current liabilities for Q3 2021 of $3,890,393 then subtracted the gross profit $1,346,338 and got $2,544,055 . Take this number and divide by the number of outstanding 303,539 shares for Q3 2020 for comparison and arrive at -$8.38 a share, again negative.
Though hardly scientific it does demonstrate the difference that the revenue and reduced liabilities can make. So 3.5 times higher if applied to the $12 trading price of the time could mean a share price of $42 a share. So before the eye rolls start from those reading this consider that $42 pre-split is only .021 a share. We are trading at $2 or .001 pre-split? Even with the Jason bad mojo going on, the truth has to be somewhere in the middle in my humble opinion.
Share count this Q3 is much higher than that of 2020. Again, this post is certainly in the realm of conjecture but it is very difficult to determine what could be a bottom here under the circumstances. Notice the cost of revenue isn't much higher for 2021 despite the double revenue. They also show nearly $1.4 million in cash on the balance sheet. Who knows what Jason will do with it.
The Company is authorized to issue 1,500,000,000 shares of common stock with a par value of $0.001. All shares have equal voting rights, are non-assessable, and have one vote per share. The total number of shares of Company common stock issued and outstanding as of September 30, 2020 and December 31, 2019, respectively, was 607,077,018 and 9,692,065 shares, respectively.
Total current liabilities $9,656,268 Cash $482,715 Total current assets $568,714 Revenue $700,275 Cost of revenue $108,363 Gross profit $591,912
As of September 30, 2021, the Company is authorized to issue 1,000,000,000 shares of common stock with a par value of $0.001. All shares have equal voting rights, are non-assessable, and have one vote per share. The total number of shares of Company common stock issued and outstanding as of September 30, 2021 and December 31, 2020, respectively, was 829,518 and 522,006 shares, respectively.
Total Current Liabilities $3,890,393
Cash $1,377,579 Total current assets $1,489,798
Revenue $1,495,059 Cost of revenue $148,721 Gross profit $1,346,338
Share count 829,518
($3,890,393 - $1,346,338) / 303,539 (same share count as 2020 for comparison sake.) $2,544,055 / 303,539 = -8.38
Market Data 
Markets 
AI
